Lycera’s second immune suppression program centers on highly selective and potent RORγt antagonists. Type 17 cells (Th17, Tc17 and innate immune cells producing IL-17) play important roles in the pathogenesis of multiple autoimmune diseases. RORγ is a master transcription factor that controls the formation and function of Type 17 cells including their production of disease-causing cytokines. Scientists at Lycera have identified potent, selective and orally bioavailable RORγ antagonists that effectively suppress autoimmune diseases in animal models and inhibit production of type 17 cytokines such as IL-17A, IL-17F and IL-22. Lycera’s RORγ antagonist differentiates from existing anti-IL-17 monoclonal antibody therapy by inhibiting multiple cytokines and reducing the pathogenicity of T cells which could benefit patients with various autoimmune diseases.
Publications for RORγ Antagonists
Journal of Allergy and Clinical Immunology 2015. “RORγt inhibitors suppress TH17 responses in inflammatory arthritis and inflammatory bowel disease.” Jelle de Wit, , M. Hussein Al-Mossawi, Michael H. Hühn, Carolina V. Arancibia-Cárcamo, Karen Doig, Benjamin Kendrick, Roger Gundle, Peter Taylor, Terri Mcclanahan, Erin Murphy, Hongjun Zhang, Ken Barr, J. Richard Miller, Xiao Hu, Thomas D. Aicher, Rodney W. Morgan, Gary D. Glick, Dennis Zaller, Craig Correll, Fiona Cowrie a d Paul Bowness